Integrating alternative therapies in overcoming chemotherapy resistance in tumors
- PMID: 39961936
- DOI: 10.1007/s11033-025-10361-1
Integrating alternative therapies in overcoming chemotherapy resistance in tumors
Abstract
Chemotherapy-resistant tumors present a significant challenge in oncology, often leading to treatment failures owing to mechanisms such as genetic mutations, drug efflux, altered metabolism, and adaptations within the tumor microenvironment. These factors limit the effectiveness of treatment and contribute to tumor resistance. This review highlights the role of alternative therapies aimed at overcoming resistance mechanisms. Several alternative strategies with high efficacy rate against tumor resistance are being explored, including targeted therapies (58-64%), immunotherapy (80%), hormone therapy (22-61%), and emerging approaches such as herbal therapies (90%), probiotics (34-90%), metabolic therapies (> 50%), epigenetic therapies (51-89%), microbiome-based therapies (50%), gene therapy (67-80%), photodynamic therapy/hypothermia (86-99%), and nanotechnology (50-67%). Integrating these alternative strategies with conventional treatments has the potent-al to augment the therapeutic efficacy and patient outcomes. Despite this progress, limitations in cancer therapeutics include the lack of predictive biomarkers, resistance mechanisms, and tumor heterogeneity, all of which contribute to treatment failure and relapse. To address these limitations, advancements in molecular diagnostics, as well as early detection through liquid biopsies, and the use of biomarkers to monitor resistance and guide treatment are crucial. Additionally, expanding clinical trials is essential to validate new therapies and improve patient outcomes.
Keywords: Alternative therapies; Chemotherapy; Combinatorial approaches; Drug resistance; Tumors.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Conflict of interests: The authors declare no competing interests. Ethical approval: Not applicable.
Similar articles
-
Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.Drug Resist Updat. 2015 Nov;23:69-78. doi: 10.1016/j.drup.2015.08.004. Epub 2015 Aug 22. Drug Resist Updat. 2015. PMID: 26341193 Review.
-
Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy.Nutrients. 2024 Oct 31;16(21):3741. doi: 10.3390/nu16213741. Nutrients. 2024. PMID: 39519572 Free PMC article. Review.
-
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.Int J Mol Sci. 2025 Feb 25;26(5):1988. doi: 10.3390/ijms26051988. Int J Mol Sci. 2025. PMID: 40076613 Free PMC article. Review.
-
Targeted Drug Nanodelivery and Immunotherapy for Combating Tumor Resistance.Comb Chem High Throughput Screen. 2025;28(4):561-581. doi: 10.2174/0113862073296206240416060154. Comb Chem High Throughput Screen. 2025. PMID: 38676501 Review.
-
Overcoming cancer therapy resistance: From drug innovation to therapeutics.Drug Resist Updat. 2025 Jul;81:101229. doi: 10.1016/j.drup.2025.101229. Epub 2025 Mar 8. Drug Resist Updat. 2025. PMID: 40081221 Review.
References
-
- WHO. (2024, February 1). Global cancer burden growing, amidst mounting need for services. Retrieved from https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--a...
-
- Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB (2019) Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study, The Lancet. Oncology 20(6):769–780. https://doi.org/10.1016/S1470-2045(19)30163-9 - DOI - PubMed
-
- Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer drug resistance (Alhambra, Calif.), 2(2), 141–160. https://doi.org/10.20517/cdr.2019.10
-
- Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., ... & de la Lastra, J. M. P. (2023). Cancer chemotherapy and beyond Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 10(4): 1367–1401.
-
- Rahman MA, Rakib-Uz-Zaman SM, Chakraborti S, Bhajan SK, Gupta RD, Jalouli M, Parvez MAK, Shaikh MH, Hoque Apu E, Harrath AH et al (2024) Advancements in utilizing natural compounds for modulating autophagy in liver cancer: molecular mechanisms and therapeutic targets. Cells 13(14):1186. https://doi.org/10.3390/cells13141186 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical